A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a randomized, double-blind, placebo-controlled, dose-escalation Phase Ib study to evaluate the safety, tolerability, and pharmacokinetics of HB0017 following multiple dose in patients with moderate to severe plaque psoriasis.
Epistemonikos ID: c3d6b5507d816a3f962379df8529ffe847166764
First added on: May 13, 2024